Healthcare sales up 15% at Novo Nordisk:
This article was originally published in Clinica
Healthcare sales at Novo Nordisk (Denmark) rose 15% to DKr 2,365 million ($438 million) in the first quarter of 1995 compared with the previous year. This reflects developments in the volume/product mix, says the company. Diabetes care revenues were up DKr 1,610 in the quarter compared with 1994. Stronger sales in Germany, Japan and the UK were counteracted by a decline in US sales, which Novo blames on negative currency exchange movements. Group turnover was up 9% to DKr 3,404 million for the quarter, with net income up 15% to DKr 310 million, compared with the same period last year. The group expects overall revenues to increase some 10% in 1995.
You may also be interested in...
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.